Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 61 of 61 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins FLT3 D835Y	leukemia	predicted - resistant	Pexidartinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with FLT3-ITD positive leukemia initially responded to Pexidartinib (PLX3397) therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, FLT3 D835Y was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	predicted - resistant	Pexidartinib	Case Reports/Case Series	Actionable	In a Phase I/II trial, an acute myeloid leukemia patient harboring a FLT3-ITD was found to have acquired FLT3 D835Y following relapse on Turalio (pexidartinib) treatment (PMID: 34103301; NCT01349049).	34103301
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and D835Y in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).	27158668
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/D835Y compound mutations (PMID: 29187377).	29187377
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Dubermatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dubermatinib (TP-0903) treatment resulted in cell cycle arrest and apoptosis, induced differentiation, and inhibited growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation and FLT3 D835Y in culture, and reduced tumor growth and increased survival in cell line xenograft models (PMID: 33268594).	33268594
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Gilteritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xospata (gilteritinib) treatment inhibited growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation and FLT3 D835Y in culture, and reduced tumor growth and increased survival in cell line xenograft models (PMID: 33268594).	33268594
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 D835Y was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Crenolanib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 D835Y was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on the combination of Crenolanib (CP-868596) and Nexavar (sorafenib) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	conflicting	Crenolanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 D835Y was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Crenolanib (CP-868596) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	predicted - sensitive	Tuspetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tuspetinib (HM43239) treatment resulted in tumor regression in a cell line xenograft model of acute myeloid leukemia expressing a FLT3 ITD mutation and FLT3 D835Y (Cancer Res 2021;81(13_Suppl):Abstract nr 1257).	detail...
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	predicted - sensitive	PHI-101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PHI-101 decreased leukemia burden in a cell line xenograft model expressing FLT3 D835Y in the context of a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802).	detail...
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	resistant	Quizartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FLT3-ITD with FLT3 D835Y were resistant to treatment with Vanflyta (quizartinib) in culture and in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 D835Y and improved survival in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Foretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 D835Y, and led to improved survival in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	LAM-003	Preclinical - Patient cell culture	Actionable	In a preclinical study, LAM-003 treatment inhibited viability of an acute myeloid leukemia cell line and patient-derived cells harboring FLT3 internal tandem duplication (ITD) and FLT3 D835Y in culture (PMID: 31751472).	31751472
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) treatment in culture (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Vanflyta (quizartinib) treatment in culture (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Gilteritinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated sensitivity to Xospata (gilteritinib) treatment in culture, resulting in reduced cell viability (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	conflicting	Crenolanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated sensitivity to Crenolanib (CP-868596) treatment in culture, resulting in reduced cell viability (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	predicted - resistant	Midostaurin	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Rydapt (midostaurin) treatment in culture (PMID: 27908881).	27908881
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	predicted - sensitive	KX2-391	Preclinical - Patient cell culture	Actionable	In a preclinical study, KX2-391 treatment inhibited cell viability and decreased Flt3 phosphorylation in patient-derived acute myeloid leukemia cell lines harboring a FLT3-ITD mutation with FLT3 D835Y in culture (PMID: 34217323).	34217323
FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing a FLT3-ITD mutation and FLT3 D835Y in culture (PMID: 27780853).	27780853
FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668).	27158668
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG-806 inhibited proliferation of a cell line expressing a FLT3 exon 14 insertion (ITD) mutation and FLT3 D835Y in culture (PMID: 35499387).	35499387
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid cell line harboring FLT3 internal tandem duplication (ITD) and FLT3 D835Y did not demonstrate sensitivity to Nexavar (sorafenib) treatment in culture (PMID: 31751472).	31751472
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Tandutinib	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid cell line harboring FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Tandutinib (CT53518) treatment in culture (PMID: 31751472).	31751472
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	no benefit	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing FLT3 ITD and FLT3 D835Y did not respond to treatment with Ibrance (palbociclib) in culture (PMID: 30544932).	30544932
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	no benefit	Danusertib + Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing FLT3 ITD and FLT3 D835Y did not respond to the combination treatment of Ibrance (palbociclib) and Danusertib (PHA-739358) in culture (PMID: 30544932).	30544932
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells co-expressing FLT3-ITD with other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835Y	myeloid leukemia	resistant	A-419259	Preclinical - Cell culture	Actionable	In a preclinical study, transformed myeloid leukemia cells co-expressing FLT-ITD and FLT3 D835Y demonstrated resistance to A-419259 treatment in culture (PMID: 31790499).	31790499
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Dubermatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dubermatinib (TP-0903) inhibited growth of transformed cells expressing a FLT3-ITD mutation and FLT3 D835Y in culture (PMID: 33268594).	33268594
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	predicted - sensitive	LT-171-861	Preclinical - Cell culture	Actionable	In a preclinical study, LT-171-861 inhibited cell viability and decreased FLT3 phosphorylation in transformed cells expressing a FLT3-ITD mutation and FLT3 D835Y in culture (PMID: 33391463).	33391463
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	KX2-391	Preclinical - Cell culture	Actionable	In a preclinical study, KX2-391 treatment inhibited cell viability, decreased downstream signaling, and induced apoptosis in cells expressing a FLT3-ITD mutation with FLT3 D835Y in culture (PMID: 34217323).	34217323
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Momelotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Momelotinib (CYT387) decreased phosphorylation of Flt3 and Stat5 and inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited growth of acute myeloid leukemia cells harboring FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 ITD with FLT3 D835Y in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in acute myeloid leukemia cells harboring FLT3 ITD with FLT3 D835Y in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3 ITD with FLT3 D835Y were resistant to Vanflyta (quizartinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib (CP-868596) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y were resistant to treatment with Vanflyta (quizartinib) in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	conflicting	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y were sensitive to Rydapt (midostaurin) treatment in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y were sensitive to Crenolanib (CP-868596) treatment in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	resistant	Sitravatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD mutation with FLT3 D835Y were resistant to treatment with Sitravatinib (MGCD516) in culture (PMID: 36691065).	36691065
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	conflicting	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) inhibited phosphorylation of Flt3 and Stat5 and viability in a transformed cell line expressing a FLT3-ITD mutation and FLT3 D835Y in culture (PMID: 31102119).	31102119
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) inhibited viability in an acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 D835Y in culture (PMID: 31102119).	31102119
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	PLM-101	Preclinical - Cell culture	Actionable	In a preclinical study, PLM-101 inhibited proliferation in cells expressing FLT3 D835Y in the context of a FLT3-ITD mutation in culture (PMID: 37392657).	37392657
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited viability in an acute myeloid leukemia cell line harboring FLT3 ITD and expressing FLT3 D835Y in culture (PMID: 37992684).	37992684
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Foretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3-ITD with FLT3 D835Y in culture (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3-ITD with FLT3 D835Y in culture (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, primary patient-derived acute myeloid leukemia blasts harboring FLT3-ITD with FLT3 D835Y were less sensitive to Vanflyta (quizartinib) in culture (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	sensitive	Ningetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 D835Y in culture (PMID: 38978049).	38978049
FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	predicted - sensitive	Tuspetinib	Preclinical	Actionable	In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and D835Y in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293).	detail...

Showing 1 to 61 of 61 entries

Filter rows:

Profile Name	FLT3 exon 14 ins FLT3 D835Y
Gene Variant Detail	FLT3 D835Y (gain of function) FLT3 exon 14 ins (gain of function - predicted)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting